Browsing Tag
Memo Therapeutics
3 posts
Can potravitug justify Ipsen’s €700m-plus Memo Therapeutics acquisition?
Ipsen is acquiring Memo Therapeutics to secure potravitug, a clinical-stage antibody targeting a serious kidney transplant complication. The structure limits Ipsen’s upfront exposure while placing the larger valuation behind clinical, regulatory and commercial success.
Memo Therapeutics secures $15.5m in Series B to propel antibody development for COVID-19 and BK virus treatment
Memo Therapeutics, a Swiss biotech company, has successfully raised CHF 14 million (approximately $15.56 million) in a Series…
Northway Biotechpharma to manufacture Memo’s Covid1-9 drug MTX-COVAB
Memo Therapeutics (MTx), a Swiss biotech company, has entered into a partnership with Northway Biotechpharma, under which the…